Cargando…
Prognostic significance of anti-p53 and anti-KRas circulating antibodies in esophageal cancer patients treated with chemoradiotherapy
BACKGROUND: P53 mutations are an adverse prognostic factor in esophageal cancer. P53 and KRas mutations are involved in chemo-radioresistance. Circulating anti-p53 or anti-KRas antibodies are associated with gene mutations. We studied whether anti-p53 or anti-KRas auto-antibodies were prognostic fac...
Autores principales: | Blanchard, Pierre, Quero, Laurent, Pacault, Vincent, Schlageter, Marie-Helene, Baruch-Hennequin, Valerie, Hennequin, Christophe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3338390/ https://www.ncbi.nlm.nih.gov/pubmed/22448886 http://dx.doi.org/10.1186/1471-2407-12-119 |
Ejemplares similares
-
Salvage radiotherapy for patients with PSA relapse after radical prostatectomy: a single institution experience
por: Quero, Laurent, et al.
Publicado: (2008) -
Clinical significance of circulating anti-p53 antibodies in European patients with hepatocellular carcinoma
por: Saffroy, R, et al.
Publicado: (1999) -
Radiotherapy for gastric mucosa-associated lymphoid tissue lymphoma
por: Quéro, Laurent, et al.
Publicado: (2021) -
Urinary function and quality of life after radiotherapy for prostate cancer in patients with prior history of surgical treatment for benign prostatic hyperplasia
por: Guilhen, Mélanie, et al.
Publicado: (2018) -
Pattern of p53 protein expression is predictive for survival in chemoradiotherapy-naive esophageal adenocarcinoma
por: Ten Kate, Fiebo J.C., et al.
Publicado: (2017)